Analysis | Values | Cases avoided | Deaths averted | Cost (savings) in billions of $ |
---|---|---|---|---|
Base-case | -- | 4,726,000 | 108,500 | (7.34) |
Re-calibrated using current non-pandemic incidence distribution by age | -- | 4,430,000 | 73,100 | (4.8) |
Incidence and case-fatality of bacteremic pneumonia - reduced by 50% | -- | 3,873,000 | 39,600 | (4.09) |
Case-fatality rates for IPD and pneumonia - increased to 20% | Â | -- | 201,000 | (7.33) |
Herd effect on pneumonia | Â | Â | Â | Â |
   Low (0%) | 0% | 4,106,000 | 59,600 | (5.61) |
   High16 | 15% - 26% | 5,345,000 | 157,300 | (9.07) |
Incidence of IPD (per 100,000) | Â | Â | Â | Â |
   Low (-10%) | 296 - 8,365 | 4,689,000 | 102,700 | (6.77) |
   High (+10%) | 383 - 10,224 | 4,763,000 | 114,200 | (7.90) |
Incidence of all-cause pneumonia (per 100,000) | Â | Â | Â | Â |
   Low (-10%) | 5 - 165 | 4,681,000 | 103,700 | (7.17) |
   High (+10%) | 7 - 202 | 4,770,000 | 113,300 | (7.50) |
Vaccine effectiveness on AOM (<2 Yr) | Â | Â | Â | Â |
   Low21 | 6% | 2,687,000 | -- | (6.81) |
   High27 | 42% | 10,444,000 | -- | (8.80) |
Vaccine coverage (<2) | Â | Â | Â | Â |
   Low (-10%) | 78% | 4,661,000 | 107,900 | (7.40) |
   High (+10%) | 96% | 4,790,000 | 109,000 | (7.27) |
Price of vaccine | Â | Â | Â | Â |
   Low (-10%) | $68.78 | -- | -- | (7.44) |
   High (+10%) | $84.06 | -- | -- | (7.24) |
Influenza treatment | Â | Â | Â | Â |
   Low (-10%) | 8% - 16% | 4,728,000 | -- | (7.34) |
   High (+10%) | 14% - 26% | 4,725,000 | -- | (7.34) |
Case-fatality from IPD | Â | Â | Â | Â |
   Low (-10%) | 0.8% - 25% | -- | 102,400 | -- |
   High (+10%) | 0.9% - 30% | -- | 114,500 | -- |
Case-fatality from all-cause pneumonia | Â | Â | Â | Â |
   Low (-10%) | 0.4% - 4.7% | -- | 103,700 | -- |
   High (+10%) | 0.5% - 6% | -- | 113,300 | -- |